Upfront Briefing
Washington is suddenly the main biotech catalyst: twelve former FDA commissioners are publicly warning that vaccine policy changes and a new CDER chief could upend the agency’s playbook, while FDA is also floating user-fee tweaks that favor early-stage trials onshore and penalize ex-US Phase 1 work.
On the clinical side, Capricor is back with positive Phase 3 data in Duchenne cardiomyopathy after a prior rejection, Pharvaris and a hair-loss contender notch late-stage wins, and Bristol Myers has to extend a key Alzheimer’s psychosis trial after irregularities. Capital is still flowing: Pfizer-allied molecular glue shop Triana lands $120M, Biogen launches a new corporate VC arm, a "next-gen" CRO shows up with 350+ US sites, and Medtronic’s Hugo robot clears the FDA as one home-care startup quietly exits.
All of this is landing as XBI rips higher alongside the broader tape, with fresh NEJM pieces on vaccines and FDA governance underscoring that the policy and data debates are moving just as fast as the stocks.
Market Moves
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6849.72 |
0.30% |
16.46% |
| Nasdaq 100 |
25606.54 |
0.20% |
21.87% |
| Russell 2000 |
2512.14 |
1.91% |
12.64% |
| SPDR S&P Biotech (XBI) |
121.83 |
2.84% |
35.28% |
| Nasdaq Biotechnology Index (NBI) |
5764.60 |
1.96% |
33.73% |
Top 3 Headlines
|
1
|
Former FDA Commissioners Criticize Vaccine Policy Changes
|
Twelve former FDA commissioners have raised concerns over recent vaccine policy changes and the appointment of a new CDER head, signaling potential shifts in regulation and leadership.
Why it matters: Concerns from former FDA leaders and a controversial appointment could signal significant shifts in vaccine regulation and drug division leadership.
Source: BioCentury
More:
Endpoints News (CDER head) ·
Endpoints News (vaccine changes) ·
Endpoints News (Covid data) ·
BioSpace
|
|
2
|
Capricor Reports Positive Phase 3 Data for DMD Therapy
|
Capricor Therapeutics announced positive Phase 3 results for its Duchenne Muscular Dystrophy therapy, potentially paving the way for approval after a previous rejection.
Why it matters: Positive Phase 3 results for Capricor's DMD therapy could lead to approval after a previous rejection, offering a new treatment for a rare disease.
Source: BioPharma Dive
More:
BioCentury ·
Endpoints News ·
BioSpace
|
|
3
|
FDA Proposes User Fee Changes for Clinical Trials
|
The FDA is proposing changes to user fees, aiming to incentivize early-stage clinical trials within the US while adding fees for overseas development.
Why it matters: New FDA user fees could shift early-stage clinical trial locations, impacting drug development strategies and costs for biopharma companies.
Source: Fierce Biotech
More:
Endpoints News
|
More Headlines
- Pharvaris' oral pill achieved success in a late-stage trial for hereditary angioedema, positioning it as a potential new treatment for the rare swelling disorder — BioPharma Dive.
- Bristol Myers Squibb has extended a key trial for its Alzheimer's psychosis drug, Cobenfy, following the discovery of irregularities — BioPharma Dive.
- A hair loss drug has met its primary endpoint in a Phase 3 trial, but experts remain underwhelmed by the data, suggesting limited market enthusiasm — STAT.
- Biogen is pivoting its strategy with the launch of a new corporate venture capital fund, Biogen New Ventures, to invest in upstream science — BioCentury.
- Home care startup Inbound Health has ceased operations, reflecting ongoing challenges within the health tech sector — Endpoints News.
- Black Diamond Therapeutics has reported mid-stage lung cancer data and is actively seeking a partner to advance its drug development — Endpoints News.
- Medtronic's Hugo surgical robot has received US clearance, expanding its market presence and increasing competition in surgical robotics — Fierce Biotech.
- Avetra, a new contract research organization, has launched with access to over 350 US clinical trial sites, aiming to modernize clinical research — Fierce Biotech.
Deal Flow
M&A / BD&L
- Royalty bestows Zenas with $300M deal to push autoimmune asset across FDA finish line
— Fierce Biotech.
VC & Private Financings
- Triana, a molecular glue startup allied with Pfizer, has successfully raised $120 million in Series B funding to advance its drug discovery platform — Endpoints News.
- Biogen is pivoting its strategy with the launch of a new corporate venture capital fund, Biogen New Ventures, to invest in upstream science — BioCentury.
IPOs & Follow-Ons
- No notable IPOs & Follow-Ons in the last 24 hours.
|
|
Thanks for reading BioBucks — the fastest way to scan what actually moved biotech, policy, and capital since yesterday.
This content is for information only and is not investment or medical advice.
|
|